CellPryme-M question, page-20

Thanks @hottod that was the most informative response on the topic so far, certainly matches up with what Steven has commentated on regulation wise...Steven would be well informed & keeps in constant communication with the FDA...He also has not tried to oversell CellPryme so I trust his information FDA wise.

The Biden administration have come out & said they are going to pull out all stops on cancer.

That means minor adjustments like CellPryme would only need submissions to FDA if at all, or what's the point?

We are talking minor % changes to cell therapies involving our own cells, if complete trials over a decade were required every time an iteration or improvement is discovered the sector would be dead in the water.

Forgetting licensing and royalties, CellPryme would have to be adding long term value for shareholders & increasing PTX profile as a potential takeover target.

CellPryme is a big deal, both as a revenue stream long term but for our own in-house CAR-T programs...OmniCar was already the most exciting CAR-T program in the world in my opinion and it just got further turbo charged.

Holy grail right there.